Johnson & Johnson
JNJ·NASDAQNextSignal Score™
AI-powered rating
Stock Analysis Summary
Moderates Umsatzwachstum, Negatives EPS-Wachstum, Hohe Bruttomarge, Starke Eigenkapitalrendite.
KGV 24.4 – günstig, KUV attraktiv, KBV attraktiv, Analysten bullish.
Negativer Trend, Beta 0.19 – defensiv.
Abwärtstrend aktiv.
RSI 44.6 – neutrales Momentum.
Johnson & Johnson stock is currently trading at $270.47, moving within a neutral market environment.
🚀 What is happening currently?
Johnson & Johnson continues to advance its strategic focus in the fields of medical technology and biotechnology. The company recently announced the first commercial installation of the OTTAVA™ robotic system in a US hospital, marking a significant milestone for the division. Furthermore, the company is strengthening its pipeline through the planned acquisition of Ollin Biosciences for $2.2 billion to expand its presence in ophthalmology. These moves underscore a focus on innovation, even as the company remains confronted with the challenges of ongoing legal disputes.
🔍 Technical Analysis
The current price of $270.47 is above the EMA50 ($269.04) and the EMA200 ($248.57), suggesting an improved broader trend, while it remains just below the EMA20 ($273.64). With an RSI of 49.9, the stock is moving in a neutral zone. The MACD at 2.480 is below the signal value of 3.780, indicating weakening momentum. The stock is trading below resistance at $275.53, while the next support levels are at $263.83 and $260.68. Since the price is significantly below the 52W high of $290.25 but well above the 52W low of $199.91, the price structure appears consolidated, albeit currently moving sideways.
📊 Fundamental Situation
The fundamental data reflects a company growing through targeted acquisitions and product innovations. An EPS of $2.9371 is expected for the coming quarter, with quarterly results scheduled for 01/26/2027. As the company has historically faced special charges due to legal disputes, profitability is significantly influenced by the operational implementation of new strategies. The fundamental data is somewhat complex, as it includes both strong operational cash flows and the costs associated with strategic investments.
🎯 Analyst Expectations
Analysts currently rate the stock mostly as cautious to neutral. The average price target is above the current level, implying limited upside potential.
💡 Market Assessment
With a NextSignal Score of 56/100, the stock is classified as neutral. This value reflects the current uncertainty arising from the combination of sideways technical movement and fundamental challenges. There is currently no signal justifying a clear trend in either direction. Investors should closely monitor further developments regarding legal disputes as well as the integration of new technologies. A neutral stance is appropriate given the current data.
🔍 What to watch for
- Legal disputes: Potential new developments or provisions in connection with the talc lawsuits could weigh on the share price in the short term.
- OTTAVA market launch: The success of the commercial rollout of the robotic system is crucial for the growth of the MedTech division.
- Pipeline integration: The successful integration of Ollin Biosciences and progress in clinical trials are essential for long-term valuation.
Technical analysis
Last 60 trading days · Live data from Yahoo Finance
- • Price action over the last few weeks at a glance.
- • EMA lines help identify the prevailing trend direction.
Fundamentals & News
Live dataCompany

Johnson & Johnson
Johnson & Johnson is a US-based multinational corporation primarily operating in the pharmaceutical industry. The company develops, manufactures, and distributes a diverse range of medical products and pharmaceutical solutions for global healthcare. Its core business focuses on the research and development of innovative medicines and advanced medical technologies.
Fundamentals
Key metrics
Latest News
Recent reports
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
3 Reasons Dividend Aristocrats Belong in Your Roth IRA Before You Retire
5 Dividend Kings to Buy for Lifelong Income Before the End of November
How Retirees Can Turn $450,000 Into Passive Income With These 5 Dividend Stocks

Dell, HP Earnings In Focus In A Muted Week For Markets

